New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
December 20, 2012
08:39 EDTDNDN, NVSDendreon sells New Jersey facility to Novartis for $43M
Dendreon (DNDN) sold its immunotherapy manufacturing facility based in Morris Plains, New Jersey, to Novartis (NVS) for $43M in cash. The facility features capabilities to manufacture Provenge (sipuleucel-T), the first autologous cellular immunotherapy to receive FDA approval for the treatment of asymptomatic or minimally symptomatic metastatic castrate resistant prostate cancer.
News For DNDN;NVS From The Last 14 Days
Check below for free stories on DNDN;NVS the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
August 20, 2014
12:06 EDTNVSNovartis treatment for pigmented villonodular synovitis gets orphan designation
According to a post on the FDA's website, Novartis' recombinant human monoclonal antibody of the IgG1 kappa class against human macrophage colony-stimulating factor received orphan designation. Reference Link
05:17 EDTNVSNovartis provides drug candidate compounds to TB Alliance
Subscribe for More Information
August 19, 2014
13:00 EDTDNDNDendreon alternatives could leave no equity value, says Brean Capital
Subscribe for More Information
05:11 EDTNVSGamida Cell announces investment, option agreement with Novartis
Subscribe for More Information
August 18, 2014
07:35 EDTNVSApricus Biosciences launches topical ED treatment in Germany
Subscribe for More Information
August 12, 2014
16:32 EDTDNDNOn The Fly: Closing Wrap
Subscribe for More Information
12:37 EDTDNDNOn The Fly: Midday Wrap
Subscribe for More Information
09:35 EDTDNDNActive equity options trading on open
Active equity options trading on open according to Track Data: AAPL GOOG C TSL EXAS BAC DNDN JNJ TSLA
09:21 EDTDNDNOn The Fly: Pre-market Movers
Subscribe for More Information
08:16 EDTDNDNDendreon reports Q2 EPS (10c), consensus (20c)
Reports Q2 revenue $82.16M, consensus $82.2M. Results reported last night in a regulatory filing. Dendreon stated in the filing, "Our stock price is well below the $51.24 effective conversion price for the 2016 Notes, making it unlikely that the holders of the 2016 Notes will exercise their conversion right. As a result, we assume that, absent the execution of a transaction of the type described below, we will be required under the terms of the 2016 Notes to repay the full $620 million principal amount at maturity. Based on our currently anticipated operating results, however, and even assuming the realization of future expense reductions that we plan to make and product revenues that we forecast, there is a significant risk that, while we believe we have sufficient cash to meet our ordinary course obligations for at least the next twelve months, we will not be able to repay or refinance the 2016 Notes. Accordingly, we are currently considering alternatives to the repayment of the 2016 Notes in cash, including alternatives that could result in leaving our current stockholders with little or no financial ownership of Dendreon. Our Board of Directors will consider any strategic alternatives that might be presented by third parties, though there can be no guarantee that any such alternative will provide value for the Company’s stockholders."
08:12 EDTDNDNDendreon Provenge sales seem to be stabilizing, says Maxim
Maxim says sales of Dendreon's Provenge look to be stabilizing after the company disclosed Q2 revenue of $82M, versus the prior quarter's $68M. However, Maxim thinks the competitive landscape is becoming more difficult and that the probability of Dendreon being acquired is falling. It keeps a Hold rating on the stock.
07:34 EDTDNDNDendreon drops 12% to $1.86 after saying 'no guarantee' for shareholders
07:32 EDTDNDNDendreon says alternatives could leave shareholders with no ownership
Dendreon disclosed last night in its quarterly filing, "Based on our currently anticipated operating results, however, and even assuming the realization of future expense reductions that we plan to make and product revenues that we forecast, there is a significant risk that, while we believe we have sufficient cash to meet our ordinary course obligations for at least the next twelve months, we will not be able to repay or refinance the 2016 Notes. Accordingly, we are currently considering alternatives to the repayment of the 2016 Notes in cash, including alternatives that could result in leaving our current stockholders with little or no financial ownership of Dendreon. Our Board of Directors will consider any strategic alternatives that might be presented by third parties, though there can be no guarantee that any such alternative will provide value for the Company’s stockholders."
August 11, 2014
05:18 EDTNVSNovartis reports LCZ696 significantly reduced cardiovascular deaths
New data revealing the reduction in cardiovascular, or CV, deaths with Novartis' LCZ696 in patients with heart failure with reduced ejection fraction, or HF-REF, will be presented at the European Society of Cardiology, or ESC, Congress 2014. The 8,442 patient study, PARADIGM-HF, was specifically designed to see if LCZ696 could increase survival over and above what can be achieved with ACE-inhibitor enalapril in addition to current best treatment in HF-REF patients. In March the Data Monitoring Committee overseeing the study confirmed those given LCZ696 were significantly less likely to die from CV causes, leading to the trial being closed early. LCZ696 significantly reduced cardiovascular deaths in head to head study against enalapril, in addition to current best treatment, in patients with HF-REF. PARADIGM-HF is the largest heart failure study ever conducted and was stopped early in March due to compelling efficacy. LCZ696 was recently granted FDA Fast Track status and rolling submission expected to be complete by end of year.
August 8, 2014
06:51 EDTNVSJudge rules DOJ can pursue Novartis kickback suit, Reuters says
U.S. District Judge Colleen McMahon ruled that the U.S. Department of Justice is allowed to continue its False Claims Act lawsuit versus Novartis regarding allegations that the company used kickbacks to increase sales of medications covered by Medicare and Medicaid, according to Reuters, citing comments from McMahon. Reference Link
August 7, 2014
08:38 EDTNVSEnanta's HCV NS5A inhibitor EDP-239 advances into combination studies
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use